Trends in prescribing patterns of antiepileptic drugs among older adult inpatients in a Brazilian tertiary center

ABSTRACT

Background: Data on prescribing patterns of antiepileptic drugs (AEDs) to older adult inpatients are limited. Objective: To assess changes in prescribing patterns of AEDs to older adult inpatients with late-onset epilepsy between 2009-2010 and 2015-2019, and to interpret any unexpected patterns over the 2015-2019 period. Methods: Patients aged ≥60 years with late-onset epilepsy from a tertiary center were selected. Demographic data, seizure characteristics and etiology, comorbidities, and comedications were analyzed, in addition to prescription regimens of inpatients taking AEDs to treat epilepsy. AED regimens were categorized into two groups: group 1 included appropriate AEDs (carbamazepine, oxcarbazepine, valproic acid, gabapentin, clobazam, lamotrigine, levetiracetam, topiramate, and lacosamide); and group 2 comprised suboptimal AEDs (phenytoin and phenobarbital). Multivariate logistic regression analysis was performed to identify risk factors for prescription of suboptimal AEDs. Results: 134 patients were included in the study (mean age: 77.2±9.6 years). A significant reduction in the prescription of suboptimal AEDs (from 73.3 to 51.5%; p<0.001) was found; however, phenytoin remained the most commonly prescribed AED to older adult inpatients. We also found an increase in the prescription of lamotrigine (from 5.5 to 33.6%) and levetiracetam (from 0 to 29.1%) over time. Convulsive status epilepticus (SE) and acute symptomatic seizures associated with remote and progressive etiologies were risk factors for the prescription of suboptimal AEDs. Conclusions: Phenytoin was the main suboptimal AED prescribed in our population, and convulsive SE and acute symptomatic seizures associated with some etiologies were independent risk factors for phenytoin prescription. These results suggest ongoing commitment to reducing the prescription of suboptimal AEDs, particularly phenytoin in Brazilian emergence rooms.

RESUMO

Introdução: Os dados referentes à prescrição de drogas antiepilépticas (DAE) em pacientes idosos hospitalizados são limitados. Objetivo: Avaliar as mudanças no padrão de prescrição de DAE em idosos hospitalizados com epilepsia de início tardio, entre 2009-2010 e 2015-2019, e interpretar quaisquer padrões inesperados no período de 2015-2019. Métodos: Foram selecionados pacientes com ≥60 anos com epilepsia de início tardio admitidos em um centro terciário. Analisamos os dados demográficos, as características e etiologia das crises, as comorbidades e as comedicações. Foram avaliados os esquemas de prescrição das DAE no tratamento de epilepsia para pacientes internados. Os regimes de DAE foram categorizados em dois grupos: o grupo 1 incluiu as DAE apropriadas (carbamazepina, oxcarbazepina, ácido valproico, gabapentina, clobazam, lamotrigina, levetiracetam, topiramato e lacosamida); e o grupo 2 compreendeu as DAE subótimas (fenitoína e fenobarbital). A análise de regressão logística multivariada foi realizada para identificar fatores de risco para prescrição de DAE subótimas. Resultados: Foram incluídos 134 pacientes (idade média: 77,2±9,6 anos). Encontramos uma redução significativa do uso das DAE subótimas (73,3 para 51,5%; p<0.001); entretanto, a fenitoína permaneceu sendo a DAE mais prescrita para os idosos hospitalizados. Também encontramos um aumento na prescrição da lamotrigina (5,5 para 33,6%) e do levetiracetam (0 para 29,1%) no período. O estado de mal epiléptico (EME) convulsivo e as crises agudas sintomáticas que estiveram associadas a etiologias remotas e progressivas foram fatores de risco para prescrição de DAE subótimas. Conclusões: A fenitoína foi a principal DAE subótima prescrita em nossa população, e o EME convulsivo e as crises agudas sintomáticas associadas a algumas etiologias foram fatores independentes de risco para a prescrição da fenitoína. Esses resultados sugerem a necessidade de compromisso contínuo para reduzir a prescrição de DAE subótimas, particularmente a fenitoína nas salas de emergência brasileiras.

Keywords:

Aged - Antiepileptic Drugs - Epilepsy - Inpatients - Seizures

Palavras-chave:

Idoso - Anticonvulsivantes - Epilepsia - Paciente Internados - Convulsões

• References

• 1 Centers for Disease C, Prevention. Trends in aging--United States and worldwide. MMWR. 2003 Jan;52(6):101-4,6.
• 2 Liu S, Yu W, Lu Y. The causes of new-onset epilepsy and seizures in the elderly. Neuropsychiatr Dis Treat. 2016 Jun;12:1425-34. https://doi.org/10.2147/NDT.S107905
• 3 Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000 Apr;355(9213):1441-6. https://doi.org/10.1016/S0140-6736(00)02149-8.
• 4 Trinka E, Bauer G, Oberaigner W, Ndayisaba JP, Seppi K, Granbichler CA. Cause-specific mortality among patients with epilepsy: Results from a 30-year cohort study. Epilepsia. 2013 Mar;54(3):495-501. https://doi.org/10.1111/epi.12014
• 5 Lezaic N, Gore G, Josephson CB, Wiebe S, Jette N, Keezer MR. The medical treatment of epilepsy in the elderly: A systematic review and meta-analysis. Epilepsia. 2019 Jul;60(7):1325-40. https://doi.org/10.1111/epi.16068
• 6 Kaur U, Chauhan I, Gambhir IS, Chakrabarti SS. Antiepileptic drug therapy in the elderly: a clinical pharmacological review. Acta Neurol Belg. 2019 Jun;119(2):163-73. https://doi.org/10.1007/s13760-019-01132-4
• 7 Brodie MJ, Kwan P. Newer drugs for focal epilepsy in adults. BMJ. 2012 Jan;344:e345. https://doi.org/10.1136/bmj.e345
• 8 Pugh MJ, Foreman PJ, Berlowitz DR. Prescribing antiepileptics for the elderly: differences between guideline recommendations and clinical practice. Drugs Aging. 2006 Nov;23(11):861-75. https://doi.org/10.2165/00002512-200623110-00002
• 9 Pugh MJ, Cramer J, Knoefel J, Charbonneau A, Mandell A, Kazis L, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc. 2004 Mar;52(3):417-22. https://doi.org/10.1111/j.1532-5415.2004.52115.x
• 10 Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005 Sep;7 Suppl 1:S1-64; quiz S65-7. https://doi.org/10.1016/j.yebeh.2005.06.001
• 11 Pugh MJ, Van Cott AC, Cramer JA, Knoefel JE, Amuan ME, Tabares J, et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology. 2008 May;70(22 Pt 2):2171-8. https://doi.org/10.1212/01.wnl.0000313157.15089.e6
• 12 Assis TR, Nascimento OJ, Costa G, Bacellar A. Antiepileptic drugs patterns in elderly inpatients in a Brazilian tertiary center, Salvador, Brazil. Arq Neuro-Psiquiatr. 2014 Nov;72(11):874-80. https://doi.org/10.1590/0004-282X20140151
• 13 Ruggles KH, Haessly SM, Berg RL. Prospective study of seizures in the elderly in the Marshfield Epidemiologic Study Area (MESA). Epilepsia. 2001 Dec;42(12):1594-9. https://doi.org/10.1046/j.1528-1157.2001.35900.x
• 14 Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. https://doi.org/10.1111/epi.12550
• 15 Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015 Oct;56(10):1515-23. https://doi.org/10.1111/epi.13121
• 16 Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30. https://doi.org/10.1111/epi.13670
• 17 Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010 Apr;51(4):671-5. https://doi.org/10.1111/j.1528-1167.2009.02285.x
• 18 Karceski S. Acute symptomatic seizures and systemic illness. Continuum (Minneap Minn). 2014 Jun;20(3 Neurology of Systemic Disease):614-23. https://doi.org/10.1212/01.CON.0000450969.61204.6f
• 19 Phabphal K, Geater A, Limapichat K, Sathirapanya P, Setthawatcharawanich S. Risk factors of recurrent seizure, co-morbidities, and mortality in new onset seizure in elderly. Seizure. 2013 Sep;22(7):577-80. https://doi.org/10.1016/j.seizure.2013.04.009
• 20 No authors listed. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. Jul-Aug 1989;30(4):389-99. https://doi.org/10.1111/j.1528-1157.1989.tb05316.x
• 21 Maxwell H, Hanby M, Parkes LM, Gibson LM, Coutinho C, Emsley HC. Prevalence and subtypes of radiological cerebrovascular disease in late-onset isolated seizures and epilepsy. Clin Neurol Neurosurg. 2013 May;115(5):591-6. https://doi.org/10.1016/j.clineuro.2012.07.009
• 22 Gavvala JR, Schuele SU. New-onset seizure in adults and adolescents: a review. JAMA. 2016 Dec;316(24):2657-68. https://doi.org/10.1001/jama.2016.18625
• 23 Prados-Torres A, Calderon-Larranaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014 Mar;67(3):254-66. https://doi.org/10.1016/j.jclinepi.2013.09.021
• 24 Watkins L, O'Dwyer M, Shankar R. New anti-seizure medication for elderly epileptic patients. Expert Opin Pharmacother. 2019 Sep;20(13):1601-8. https://doi.org/10.1080/14656566.2019.1618272
• 25 Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005 Jun;64(11):1868-73. https://doi.org/10.1212/01.WNL.0000167384.68207.3E
• 26 Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985 Jul;313(3):145-51. https://doi.org/10.1056/NEJM198507183130303
• 27 Taylor S, Tudur Smith C, Williamson PR, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2003 Apr;(2):CD002217. https://doi.org/10.1002/14651858.CD002217
• 28 Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015 Mar;56(3):450-9. https://doi.org/10.1111/epi.12926
• 29 Pohlmann-Eden B, Marson AG, Noack-Rink M, Ramirez F, Tofighy A, Werhahn KJ, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol. 2016 Aug;16(1):149. https://doi.org/10.1186/s12883-016-0663-7
• 30 Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database. Seizure. 2012 Jul;21(6):466-70. https://doi.org/10.1016/j.seizure.2012.04.014
• 31 Assis T, Bacellar A, Costa G, Pires E, Nascimento O. Predictors of early seizure recurrence among elderly inpatients admitted to a tertiary center: a prospective cohort study. Epilepsy Behav. 2019 Sep;98(Pt A):145-52. https://doi.org/110.1016/j.yebeh.2019.07.004
• 32 Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol. 2007 Dec;14(12):1317-21. https://doi.org/10.1111/j.1468-1331.2007.01970.x
• 33 Leppik IE, Birnbaum AK. Epilepsy in the elderly. Ann N Y Acad Sci. 2010 Jan;1184:208-24. https://doi.org/10.1111/j.1749-6632.2009.05113.x
• 34 Bleck TP. Seven questions about stroke and epilepsy. Epilepsy Curr. 2012 Nov-Dec;12(6):225-8. https://doi.org/10.5698/1535-7511-12.6.225